Pharmafile Logo
Pharmafocus logo
Advanced Search

Memorial Sloan Kettering Cancer Center

Showing 4 posts of 4 posts found.

Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies

April 5, 2019
Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research

Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …

News
takeda_usa_pharmaceuticals_u

Takeda unveils three new discovery and development collaborations in immuno-oncology

January 4, 2019
Medical Communications, Research and Development CAR-T, Crescendo Biologics, Memorial Sloan Kettering Cancer Center, Noile-Immune, Takeda, pharma

Takeda has revealed that it is set to bolster its novel immuno-oncology portfolio with three new research collaborations. The Japanese …

News

Memorial Sloan Kettering Chief resigns from MSD board

October 3, 2018
Research and Development MSD, Memorial Sloan Kettering Cancer Center, pharma

Dr Craig Thompson, Chief Executive of Memorial Sloan Kettering Cancer Center (MSKCC), the renowned non-profit treatment and research institution based …

News

Avacta joins major US cancer centre for CAR-T immunotherapy development

November 2, 2016
Research and Development Avacta, Memorial Sloan Kettering Cancer Center

Biotherapeutic and research reagent developer Avacta has announced it will collaborate with New York’s Memorial Sloan Kettering Cancer Center (MSK, …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024